Kairos Pharma, LTD.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
KAPA$0.49+7.3%Stored close · as of Nov 6, 2026
Contents
Item 1. Unaudited Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025
Condensed Consolidated Balance Sheets (unaudited)
(In thousands, except for share amounts and par value data)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| ASSETS | ||
| Current Assets | ||
| Cash and cash equivalents | $3,675 | $4,491 |
| Vendor advances, net | 625 | 845 |
| Prepaid expenses and other current assets | 143 | 51 |
| Total Current Assets | 4,443 | 5,387 |
| Deferred offering costs | 1,279 | 1,091 |
| Intangible assets, net | 22 | 62 |
| Total Other Assets | 1,301 | 1,153 |
| TOTAL ASSETS | $5,744 | $6,540 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | $431 | $199 |
| Total Current Liabilities | 431 | 199 |
| Commitments and contingencies | - | - |
| Shareholders’ Equity | ||
| Preferred stock, par value $0.001, 20,000,000 shares authorized; no shares issued and outstanding, respectively; | - | - |
| Common stock, par value $0.001, 100,000,000 shares authorized; 21,411,198 and 20,821,353 shares issued and outstanding, respectively; | 21 | 21 |
| Additional paid-in capital | 21,208 | 20,582 |
| Accumulated deficit | (15,916) | (14,262) |
| Total Shareholders’ Equity | 5,313 | 6,341 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $5,744 | $6,540 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.